67 related articles for article (PubMed ID: 21709686)
1. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia.
Scielzo C; Apollonio B; Scarfò L; Janus A; Muzio M; Ten Hacken E; Ghia P; Caligaris-Cappio F
Leukemia; 2011 Nov; 25(11):1760-7. PubMed ID: 21709686
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22.
Ghia P; Strola G; Granziero L; Geuna M; Guida G; Sallusto F; Ruffing N; Montagna L; Piccoli P; Chilosi M; Caligaris-Cappio F
Eur J Immunol; 2002 May; 32(5):1403-13. PubMed ID: 11981828
[TBL] [Abstract][Full Text] [Related]
3. The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia.
Giannopoulos K; Mertens D; Bühler A; Barth TF; Idler I; Möller P; Kröber A; Greiner J; Chocholska S; Dmoszyñska A; Roliñski J; Döhner H; Stilgenbauer S; Schmitt M
Leukemia; 2009 Mar; 23(3):519-27. PubMed ID: 19092852
[TBL] [Abstract][Full Text] [Related]
4. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation.
Ghia P; Chiorazzi N; Stamatopoulos K
J Intern Med; 2008 Dec; 264(6):549-62. PubMed ID: 19017179
[TBL] [Abstract][Full Text] [Related]
5. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand.
Buske C; Gogowski G; Schreiber K; Rave-Fränk M; Hiddemann W; Wörmann B
Exp Hematol; 1997 Apr; 25(4):329-37. PubMed ID: 9131008
[TBL] [Abstract][Full Text] [Related]
7. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response.
Battle TE; Wierda WG; Rassenti LZ; Zahrieh D; Neuberg D; Kipps TJ; Frank DA
Clin Cancer Res; 2003 Jun; 9(6):2166-72. PubMed ID: 12796382
[TBL] [Abstract][Full Text] [Related]
8. Study of CD40 ligand expression in B-cell chronic lymphocytic leukemia.
Brugnoni D; Rossi G; Tucci A; Cattaneo R; Airò P
Haematologica; 1995; 80(5):440-2. PubMed ID: 8566887
[TBL] [Abstract][Full Text] [Related]
9. Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro.
Tretter T; Schuler M; Schneller F; Brass U; Esswein M; Aman MJ; Huber C; Peschel C
Cell Immunol; 1998 Oct; 189(1):41-50. PubMed ID: 9758693
[TBL] [Abstract][Full Text] [Related]
10. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.
Tong AW; Papayoti MH; Netto G; Armstrong DT; Ordonez G; Lawson JM; Stone MJ
Clin Cancer Res; 2001 Mar; 7(3):691-703. PubMed ID: 11297266
[TBL] [Abstract][Full Text] [Related]
11. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.
Kater AP; Evers LM; Remmerswaal EB; Jaspers A; Oosterwijk MF; van Lier RA; van Oers MH; Eldering E
Br J Haematol; 2004 Nov; 127(4):404-15. PubMed ID: 15521917
[TBL] [Abstract][Full Text] [Related]
12. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules.
Trentin L; Zambello R; Sancetta R; Facco M; Cerutti A; Perin A; Siviero M; Basso U; Bortolin M; Adami F; Agostini C; Semenzato G
Cancer Res; 1997 Nov; 57(21):4940-7. PubMed ID: 9354461
[TBL] [Abstract][Full Text] [Related]
13. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.
Longo PG; Laurenti L; Gobessi S; Petlickovski A; Pelosi M; Chiusolo P; Sica S; Leone G; Efremov DG
Leukemia; 2007 Jan; 21(1):110-20. PubMed ID: 17024114
[TBL] [Abstract][Full Text] [Related]
14. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.
Coscia M; Pantaleoni F; Riganti C; Vitale C; Rigoni M; Peola S; Castella B; Foglietta M; Griggio V; Drandi D; Ladetto M; Bosia A; Boccadoro M; Massaia M
Leukemia; 2011 May; 25(5):828-37. PubMed ID: 21372840
[TBL] [Abstract][Full Text] [Related]
15. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles.
Plander M; Seegers S; Ugocsai P; Diermeier-Daucher S; Iványi J; Schmitz G; Hofstädter F; Schwarz S; Orsó E; Knüchel R; Brockhoff G
Leukemia; 2009 Nov; 23(11):2118-28. PubMed ID: 19657365
[TBL] [Abstract][Full Text] [Related]
16. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
[TBL] [Abstract][Full Text] [Related]
17. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity.
Yellin MJ; Sinning J; Covey LR; Sherman W; Lee JJ; Glickman-Nir E; Sippel KC; Rogers J; Cleary AM; Parker M
J Immunol; 1994 Jul; 153(2):666-74. PubMed ID: 7517421
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.
Ibrahim S; Jilani I; O'Brien S; Rogers A; Manshouri T; Giles F; Faderl S; Thomas D; Kantarjian H; Keating M; Albitar M
Cancer; 2003 Apr; 97(8):1914-9. PubMed ID: 12673718
[TBL] [Abstract][Full Text] [Related]
19. Lymphotoxin beta expression is high in chronic lymphocytic leukemia but low in small lymphocytic lymphoma: a quantitative real-time reverse transcriptase polymerase chain reaction analysis.
Nagy B; Ferrer A; Larramendy ML; Galimberti S; Aalto Y; Casas S; Vilpo J; Ruutu T; Vettenranta K; Franssila K; Knuutila S
Haematologica; 2003 Jun; 88(6):654-8. PubMed ID: 12801841
[TBL] [Abstract][Full Text] [Related]
20. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia.
Panayiotidis P; Ganeshaguru K; Foroni L; Hoffbrand AV
Leukemia; 1995 Jul; 9(7):1227-32. PubMed ID: 7543175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
